Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Alzheimer's Disease

  Free Subscription


Articles published in Brain

Retrieve available abstracts of 102 articles:
HTML format
Text format



Single Articles


    June 2019
  1. GAUBERT S, Raimondo F, Houot M, Corsi MC, et al
    EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Brain. 2019 Jun 18. pii: 5519996. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. MAASS A, Berron D, Harrison TM, Adams JN, et al
    Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Brain. 2019 Jun 14. pii: 5519092. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. NICOLL JAR, Buckland GR, Harrison CH, Page A, et al
    Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer's disease.
    Brain. 2019 Jun 3. pii: 5510133. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. PHILLIPS JS, Da Re F, Irwin DJ, McMillan CT, et al
    Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease.
    Brain. 2019;142:1701-1722.
    PubMed     Text format     Abstract available


    May 2019
  5. BRINKMALM G, Hong W, Wang Z, Liu W, et al
    Identification of neurotoxic cross-linked amyloid-beta dimers in the Alzheimer's brain.
    Brain. 2019;142:1441-1457.
    PubMed     Text format     Abstract available


  6. BATEMAN RJ, Mawuenyega KG, Wildburger NC
    The structure of amyloid-beta dimers in Alzheimer's disease brain: a step forward for oligomers.
    Brain. 2019;142:1168-1169.
    PubMed     Text format    


    April 2019
  7. PONTECORVO MJ, Devous MD, Kennedy I, Navitsky M, et al
    A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
    Brain. 2019 Apr 22. pii: 5476105. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. LYON L
    Is an epidemic of sleeplessness increasing the incidence of Alzheimer's disease?
    Brain. 2019 Apr 1. pii: 5425265. doi: 10.1093.
    PubMed     Text format    


    March 2019
  9. VOGLEIN J, Paumier K, Jucker M, Preische O, et al
    Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.
    Brain. 2019 Mar 20. pii: 5416202. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. ARENAZA-URQUIJO EM, Przybelski SA, Lesnick TL, Graff-Radford J, et al
    The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
    Brain. 2019 Mar 8. pii: 5372751. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  11. YAMAZAKI Y, Shinohara M, Shinohara M, Yamazaki A, et al
    Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression.
    Brain. 2019 Feb 15. pii: 5321132. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. FRANZMEIER N, Rubinski A, Neitzel J, Kim Y, et al
    Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease.
    Brain. 2019 Feb 15. pii: 5321130. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. GORDON BA, Blazey TM, Christensen J, Dincer A, et al
    Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Brain. 2019 Feb 11. pii: 5315649. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. TAN CH, Bonham LW, Fan CC, Mormino EC, et al
    Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.
    Brain. 2019;142:460-470.
    PubMed     Text format     Abstract available


    January 2019
  15. ZHENG Y, Liu A, Wang ZJ, Cao Q, et al
    Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease.
    Brain. 2019 Jan 22. pii: 5298257. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. PARK JC, Han SH, Yi D, Byun MS, et al
    Plasma tau/amyloid-beta1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
    Brain. 2019 Jan 21. pii: 5292577. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. ZHU BL, Long Y, Luo W, Yan Z, et al
    MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation.
    Brain. 2019;142:176-192.
    PubMed     Text format     Abstract available


    December 2018
  18. DARBY RR, Joutsa J, Fox MD
    Network localization of heterogeneous neuroimaging findings.
    Brain. 2018 Dec 14. pii: 5244188. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. KOLANKO MA, Malhotra PA
    Exploring Alzheimer's disease subtypes at the prodromal stage.
    Brain. 2018;141:3285-3287.
    PubMed     Text format    


    October 2018
  20. TEN KATE M, Dicks E, Visser PJ, van der Flier WM, et al
    Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline.
    Brain. 2018 Oct 22. pii: 5142624. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. JACOBS HIL, Buckley RF
    Where do white matter alterations dovetail with the cascade model of Alzheimer's disease?
    Brain. 2018;141:2830-2833.
    PubMed     Text format    


    September 2018
  22. ARAQUE CABALLERO MA, Suarez-Calvet M, Duering M, Franzmeier N, et al
    White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.
    Brain. 2018 Sep 19. pii: 5104289. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  23. PETYUK VA, Chang R, Ramirez-Restrepo M, Beckmann ND, et al
    The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target.
    Brain. 2018 Aug 20. pii: 5077110. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. GAO S, Casey AE, Sargeant TJ, Makinen VP, et al
    Genetic variation within endolysosomal system is associated with late-onset Alzheimer's disease.
    Brain. 2018 Aug 16. pii: 5075310. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. GAUTHIER S, Herrmann N, Rosa-Neto P
    Optimal use of cholinergic drugs in Alzheimer's disease.
    Brain. 2018 Aug 2. pii: 5064194. doi: 10.1093.
    PubMed     Text format    


  26. HAMPEL H, Cavedo E, Vergallo A
    Reply: Optimal use of cholinergic drugs in Alzheimer's disease.
    Brain. 2018 Aug 2. pii: 5064191. doi: 10.1093.
    PubMed     Text format    


  27. SAMI S, Williams N, Hughes LE, Cope TE, et al
    Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype.
    Brain. 2018;141:2500-2510.
    PubMed     Text format     Abstract available


    July 2018
  28. DANI M, Wood M, Mizoguchi R, Fan Z, et al
    Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Brain. 2018 Jul 20. pii: 5056962. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. GROTHE MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, et al
    Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
    Brain. 2018 Jul 16. pii: 5054650. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  30. COSTA C, Romoli M, Calabresi P
    Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid-beta.
    Brain. 2018 Jun 9. pii: 5035368. doi: 10.1093.
    PubMed     Text format    


  31. SEN A, Husain M
    Reply: Late onset epilepsy and Alzheimer's disease: exploring the dual pathogenic role of amyloid-beta.
    Brain. 2018 Jun 9. pii: 5035367. doi: 10.1093.
    PubMed     Text format    


  32. TIJMS BM, Visser PJ
    Chasing the start of sporadic Alzheimer's disease running in families.
    Brain. 2018;141:1589-1591.
    PubMed     Text format    


    May 2018
  33. SCELSI MA, Khan RR, Lorenzi M, Christopher L, et al
    Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci.
    Brain. 2018 May 30. pii: 5025682. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. HAMPEL H, Mesulam MM, Cuello AC, Farlow MR, et al
    The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
    Brain. 2018 May 29. pii: 5023826. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. LI D, Donohue MC
    Disease progression models for dominantly-inherited Alzheimer's disease.
    Brain. 2018;141:1244-1246.
    PubMed     Text format    


  36. HANSSON O, Mormino EC
    Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?
    Brain. 2018;141:1241-1244.
    PubMed     Text format    


    April 2018
  37. VOGEL JW, Vachon-Presseau E, Pichet Binette A, Tam A, et al
    Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.
    Brain. 2018 Apr 23. pii: 4969934. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. SABRI O, Meyer PM, Graf S, Hesse S, et al
    Cognitive correlates of alpha4beta2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Brain. 2018 Apr 17. pii: 4974320. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. MISHRA S, Blazey TM, Holtzman DM, Cruchaga C, et al
    Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE varepsilon4 genotype.
    Brain. 2018 Apr 17. pii: 4974818. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. MCALEESE KE, Walker L, Colloby SJ, Taylor JP, et al
    Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?
    Brain. 2018 Apr 13. pii: 4969931. doi: 10.1093.
    PubMed     Text format    


  41. MITO R, Raffelt D, Dhollander T, Vaughan DN, et al
    Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?
    Brain. 2018 Apr 13. pii: 4969932. doi: 10.1093.
    PubMed     Text format    


    March 2018
  42. HAMELIN L, Lagarde J, Dorothee G, Potier MC, et al
    Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
    Brain. 2018 Mar 28. pii: 4955843. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. OXTOBY NP, Young AL, Cash DM, Benzinger TLS, et al
    Data-driven models of dominantly-inherited Alzheimer's disease progression.
    Brain. 2018 Mar 22. pii: 4951528. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. JACK CR JR, Wiste HJ, Schwarz CG, Lowe VJ, et al
    Longitudinal tau PET in ageing and Alzheimer's disease.
    Brain. 2018 Mar 12. pii: 4929907. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. CHHATWAL JP, Schultz AP, Johnson KA, Hedden T, et al
    Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.
    Brain. 2018 Mar 7. pii: 4924520. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. NAKAMURA A, Cuesta P, Fernandez A, Arahata Y, et al
    Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Brain. 2018 Mar 7. pii: 4924218. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. SULTZER DL
    Cognitive ageing and Alzheimer's disease: the cholinergic system redux.
    Brain. 2018;141:626-628.
    PubMed     Text format    


    February 2018
  48. FRANZMEIER N, Duzel E, Jessen F, Buerger K, et al
    Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.
    Brain. 2018 Feb 15. pii: 4862492. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. WHITWELL JL
    Multimodal neuroimaging provides insights into the biology of Alzheimer's disease.
    Brain. 2018;141:326-329.
    PubMed     Text format    


    January 2018
  50. HOENIG MC, Bischof GN, Seemiller J, Hammes J, et al
    Networks of tau distribution in Alzheimer's disease.
    Brain. 2018 Jan 5. pii: 4791255. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. RICHTER N, Beckers N, Onur OA, Dietlein M, et al
    Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Brain. 2018 Jan 4. pii: 4788772. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. MITO R, Raffelt D, Dhollander T, Vaughan DN, et al
    Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment.
    Brain. 2018 Jan 4. pii: 4788771. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. HERHOLZ K
    Spread of tau deposits: can we trust in vivo findings?
    Brain. 2018;141:10-12.
    PubMed     Text format    


  54. GRATWICKE JP, Foltynie T
    Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's disease.
    Brain. 2018;141:7-10.
    PubMed     Text format    


    December 2017
  55. COPE TE, Rittman T, Borchert RJ, Jones PS, et al
    Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Dec 26. pii: 4775021. doi: 10.1093.
    PubMed     Text format    


  56. MAEZAWA I, Nguyen HM, Di Lucente J, Jenkins DP, et al
    Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
    Brain. 2017 Dec 18. pii: 4759461. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. LOWE VJ, Wiste HJ, Senjem ML, Weigand SD, et al
    Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Brain. 2017 Dec 8. pii: 4712020. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. FRANZMEIER N, Dyrba M
    Functional brain network architecture may route progression of Alzheimer's disease pathology.
    Brain. 2017;140:3077-3080.
    PubMed     Text format    


  59. MUTLU J, Landeau B, Gaubert M, de La Sayette V, et al
    Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers.
    Brain. 2017;140:3317-3328.
    PubMed     Text format    


  60. COLOM-CADENA M, Pegueroles J, Herrmann AG, Henstridge CM, et al
    Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies.
    Brain. 2017;140:3204-3214.
    PubMed     Text format     Abstract available


  61. SANTAMARIA-GARCIA H, Baez S, Reyes P, Santamaria-Garcia JA, et al
    A lesion model of envy and Schadenfreude: legal, deservingness and moral dimensions as revealed by neurodegeneration.
    Brain. 2017;140:3357-3377.
    PubMed     Text format     Abstract available


  62. PERRY DC, Brown JA, Possin KL, Datta S, et al
    Clinicopathological correlations in behavioural variant frontotemporal dementia.
    Brain. 2017;140:3329-3345.
    PubMed     Text format     Abstract available


  63. RODRIGUEZ-RODRIGUEZ P, Sandebring-Matton A, Merino-Serrais P, Parrado-Fernandez C, et al
    Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons.
    Brain. 2017;140:3269-3285.
    PubMed     Text format     Abstract available


    November 2017
  64. SHINOHARA M, Koga S, Konno T, Nix J, et al
    Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-beta42 in Alzheimer's disease.
    Brain. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. BUSTOS FJ, Ampuero E, Jury N, Aguilar R, et al
    Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice.
    Brain. 2017 Nov 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  66. GRINBERG LT, Heinsen H
    Light at the beginning of the tunnel? Investigating early mechanistic changes in Alzheimer's disease.
    Brain. 2017;140:2770-2773.
    PubMed     Text format    


    October 2017
  67. DU F, Yu Q, Yan S, Hu G, et al
    PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease.
    Brain. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. BEJANIN A, Schonhaut DR, La Joie R, Kramer JH, et al
    Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Brain. 2017 Oct 7. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  69. RORABAUGH JM, Chalermpalanupap T, Botz-Zapp CA, Fu VM, et al
    Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease.
    Brain. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  70. CHONG JSX, Liu S, Loke YM, Hilal S, et al
    Influence of cerebrovascular disease on brain networks in prodromal and clinical Alzheimer's disease.
    Brain. 2017 Sep 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. SCHOLL M, Ossenkoppele R, Strandberg O, Palmqvist S, et al
    Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Brain. 2017;140:2286-2294.
    PubMed     Text format     Abstract available


    August 2017
  72. DERRY PJ, Kent TA
    Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer's disease.
    Brain. 2017;140:2069-2072.
    PubMed     Text format    


  73. KIM H, Yoo J, Shin J, Chang Y, et al
    Modelling APOE varepsilon3/4 allele-associated sporadic Alzheimer's disease in an induced neuron.
    Brain. 2017;140:2193-2209.
    PubMed     Text format     Abstract available


  74. AYTON S, Fazlollahi A, Bourgeat P, Raniga P, et al
    Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline.
    Brain. 2017;140:2112-2119.
    PubMed     Text format     Abstract available


    July 2017
  75. JACOBS HIL, Hopkins DA, Mayrhofer HC, Bruner E, et al
    The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline.
    Brain. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. YEW B, Nation DA
    Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Brain. 2017;140:1987-2001.
    PubMed     Text format     Abstract available


  77. MARKUS HS
    Cerebrovascular abnormalities in Alzheimer's dementia: a more tractable treatment target?
    Brain. 2017;140:1822-1825.
    PubMed     Text format    


  78. KREISL WC
    Discerning the relationship between microglial activation and Alzheimer's disease.
    Brain. 2017;140:1825-1828.
    PubMed     Text format    


    June 2017
  79. GEORGE C, Gontier G, Lacube P, Francois JC, et al
    The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons.
    Brain. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  80. PARBO P, Ismail R, Hansen KV, Amidi A, et al
    Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Brain. 2017 May 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. DANSOKHO C, Aucouturier P, Dorothee G
    Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.
    Brain. 2017 May 12. doi: 10.1093.
    PubMed     Text format    


  82. ALVES S, Churlaud G, Klatzmann D, Cartier N, et al
    Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.
    Brain. 2017 May 12. doi: 10.1093.
    PubMed     Text format    


  83. TOSUN D, Landau S, Aisen PS, Petersen RC, et al
    Association between tau deposition and antecedent amyloid-beta accumulation rates in normal and early symptomatic individuals.
    Brain. 2017;140:1499-1512.
    PubMed     Text format     Abstract available


    April 2017
  84. HARDY J, De Strooper B
    Alzheimer's disease: where next for anti-amyloid therapies?
    Brain. 2017;140:853-855.
    PubMed     Text format    


  85. CARAVAGGIO F, Graff-Guerrero A
    Is antipsychotic sensitivity in Alzheimer's disease secondary to abnormal blood-brain barrier integrity?
    Brain. 2017;140:865-867.
    PubMed     Text format    


    March 2017
  86. YU M, Engels MM, Hillebrand A, van Straaten EC, et al
    Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study.
    Brain. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  87. ROBERTS BR, Lind M, Wagen AZ, Rembach A, et al
    Biochemically-defined pools of amyloid-beta in sporadic Alzheimer's disease: correlation with amyloid PET.
    Brain. 2017 Mar 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  88. COULTHARD E, Knight M
    Refining Alzheimer's disease diagnosis with MRI.
    Brain. 2017;140:524-526.
    PubMed     Text format    


    February 2017
  89. BANERJEE G, Kim HJ, Fox Z, Jager HR, et al
    MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Brain. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. REEVES S, McLachlan E, Bertrand J, Antonio FD, et al
    Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Brain. 2017 Feb 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. HUSAIN M
    Alzheimer's disease: time to focus on the brain, not just molecules.
    Brain. 2017;140.
    PubMed     Text format    


    January 2017
  92. PASSAMONTI L, Vazquez Rodriguez P, Hong YT, Allinson KS, et al
    18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Jan 24. pii: aww340. doi: 10.1093.
    PubMed     Text format     Abstract available


  93. FAN Z, Brooks DJ, Okello A, Edison P, et al
    An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Brain. 2017 Jan 24. pii: aww349. doi: 10.1093.
    PubMed     Text format     Abstract available


  94. HAYES JP, Logue MW, Sadeh N, Spielberg JM, et al
    Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.
    Brain. 2017 Jan 11. pii: aww344. doi: 10.1093.
    PubMed     Text format     Abstract available


  95. PONTECORVO MJ, Devous MD Sr, Navitsky M, Lu M, et al
    Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Brain. 2017 Jan 11. pii: aww334. doi: 10.1093.
    PubMed     Text format     Abstract available


  96. CAPSONI S, Malerba F, Carucci NM, Rizzi C, et al
    The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor.
    Brain. 2017;140.
    PubMed     Text format     Abstract available


  97. AHMED RM, Landin-Romero R, Collet TH, van der Klaauw AA, et al
    Energy expenditure in frontotemporal dementia: a behavioural and imaging study.
    Brain. 2017;140.
    PubMed     Text format     Abstract available


    December 2016
  98. ALVES S, Churlaud G, Audrain M, Michaelsen-Preusse K, et al
    Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.
    Brain. 2016 Dec 20. pii: aww330. doi: 10.1093.
    PubMed     Text format     Abstract available


  99. DONG A, Toledo JB, Honnorat N, Doshi J, et al
    Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Brain. 2016 Dec 20. pii: aww319. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  100. ROGAEVA E, Schmitt-Ulms G
    Does BDNF Val66Met contribute to preclinical Alzheimer's disease?
    Brain. 2016;139.
    PubMed     Text format    


    September 2016
  101. JAMES BD, Wilson RS, Boyle PA, Trojanowski JQ, et al
    TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.
    Brain. 2016.
    PubMed     Text format     Abstract available


    March 2016
  102. SCHWARZ AJ, Yu P, Miller BB, Shcherbinin S, et al
    Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Brain. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: